Abstract: The present invention provides a method for quantifying modified HDL contained in a sample, comprising binding a modified HDL to a modified HDL-binding protein, and quantifying a complex of the modified HDL-binding protein and the modified HDL, wherein the modified HDL-binding protein comprises a protein having a sequence of an L chain region of Factor V, or a variant thereof.

Abstract: The present invention provides a method for quantifying adiponectin including quantifying adiponectin while distinguishing between an adiponectin having physiological activity and an adiponectin having pathological activity in a quantification of adiponectin in body fluid.

Abstract: A fusion protein being a lipid-free reference standard having good long-term storability, which is used for measuring the quantity or quality of modified HDL, and a method for accurately, repeatability and reliably measuring high-density lipoprotein using the same. In the fusion protein, a complete protein sequence or partial fragment protein sequence for ApoA I is linked directly or via a spacer to a LOX-1 binding protein sequence that binds to a lectin-like oxidized LDL receptor: LOX-1. The method for measuring a modified high-density lipoprotein in a test sample is a method for measuring a modified high-density lipoprotein through binding of the modified high-density lipoprotein to LOX-1 and an anti-APOA I antibody, wherein, using the fusion protein as a reference standard for the modified high-density lipoprotein, the modified high-density lipoprotein in the test sample is determined by comparison with the reference standard through optical detection and/or radiation dosage detection.

Abstract: The present invention provides an anti-blood coagulant capable of selectively suppressing a pathological blood coagulation reaction without increasing the risk of major bleeding. The anti-blood coagulant in accordance with the present invention includes a binding inhibiting component that inhibits the binding of LOX-1 to at least one of factor V and factor Va.

Abstract: The present invention provides an anti-blood coagulant capable of selectively suppressing a pathological blood coagulation reaction without increasing the risk of major bleeding. The anti-blood coagulant in accordance with the present invention includes a binding inhibiting component that inhibits the binding of LOX-1 to at least one of factor V and factor Va.

Abstract: The present invention provides an oxidized LDL inhibitor that is capable of (i) binding specifically to oxidized LDL, (ii) suppressing the physiological activity of oxidized LDL, and (iii) inhibiting the uptake of oxidized LDL into cells. The oxidized LDL inhibitor according to the present invention contains a Del-1 protein as an active ingredient. The Del-1 protein consists, for example, of the amino acid sequence of SEQ ID NO: 1.

Abstract: The present invention provides an oxidized LDL inhibitor that is capable of (i) binding specifically to oxidized LDL, (ii) suppressing the physiological activity of oxidized LDL, and (iii) inhibiting the uptake of oxidized LDL into cells. The oxidized LDL inhibitor according to the present invention contains a Del-1 protein as an active ingredient. The Del-1 protein consists, for example, of the amino acid sequence of SEQ ID NO: 1.

Abstract: A compound having an excellent activity to inhibit a lectin-like oxidized LDL receptor has been identified. There are provided a drug for inhibiting a lectin-like oxidized LDL receptor characterized by including a trimeric or higher polymeric procyanidin as an active ingredient, which is useful in treating and preventing diseases, in particular, arteriosclerotic diseases, for which a lectin-like oxidized LDL receptor acts as an aggravating factor; the aforementioned drug for inhibiting a lectin-like oxidized LDL receptor, characterized in that the procyanidin is derived from a plant material selected from the group consisting of apples, grape seeds, peanut seed coats and pine barks; and a drug for preventing arteriosclerosis including a trimeric or higher polymeric procyanidin as an active ingredient, and characterized by having an activity to inhibit a lectin-like oxidized LDL receptor.

Abstract: Anti-LOX-1 antibodies having higher efficiency in action and excellent cross-reactivity are obtained. The anti-LOX-1 antibodies having higher efficiency in action and excellent cross-reactivity have been obtained, the antibodies being which specifically binds to a LOX-1 and having heavy chain CDR3 comprising one or more amino acid sequences selected from the group consisting of a) an amino acid sequence set forth in SEQ ID NO: 1, b) an amino acid sequence having 80% or more homology to the amino acid sequence a), c) an amino acid sequence having one or several amino acid deletions, substitutions, or additions in the amino acid sequence a), and d) an amino acid sequence encoded by a nucleotide sequence of a nucleic acid chain hybridizing under a stringent condition with a nucleic acid chain having a nucleotide sequence complementary to a nucleotide sequence encoding the amino acid sequence a).

Abstract: Various human monoclonal antibodies that bind to human LOX-1 and inhibit the binding of in-vivo LOX-1 ligands to LOX-1, and the LOX-1-mediated incorporation of the ligands into cells, were obtained by immunizing human antibody-producing transgenic mice (created by genetic engineering) with soluble human oxidized LDL receptor (LOX-1). Furthermore, the human monoclonal antibodies were found to be effective in preventing and treating a variety of diseases.

Abstract: Various human monoclonal antibodies that bind to human LOX-1 and inhibit the binding of in-vivo LOX-1 ligands to LOX-1, and the LOX-1-mediated incorporation of the ligands into cells, were obtained by immunizing human antibody-producing transgenic mice (created by genetic engineering) with soluble human oxidized LDL receptor (LOX-1).

Abstract: Various human monoclonal antibodies that bind to human LOX-1 and inhibit the binding of in-vivo LOX-1 ligands to LOX-1, and the LOX-1-mediated incorporation of the ligands into cells, were obtained by immunizing human antibody-producing transgenic mice (created by genetic engineering) with soluble human oxidized LDL receptor (LOX-1). Furthermore, the human monoclonal antibodies were found to be effective in preventing and treating a variety of diseases.

Abstract: The present invention provides a DNA sequence essentially encoding a mammalian vascular endothelial receptor for modified low-density lipoprotein. The sequence is set forth in the Sequence No. 1, 2 or 3.

Abstract: cDNAs encoding the human and bovine vascular endothelial receptors for modified low-density lipoprotein are provided. Also described are corresponding expression vectors, their use in the recombinant production of the encoded receptors, and the receptor polypeptides obtained thereby.